- Home
- EOSE vs LGND Comparison
EOSE vs LGND Comparison
Compare EOSE & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EOSE | LGND |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | EOSE | LGND |
|---|---|---|
| Price | $14.10 | $197.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.79 | ★ $243.50 |
| AVG Volume (30 Days) | ★ 14.0M | 191.1K |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.76 |
| EPS | N/A | ★ 2.49 |
| Revenue | $63,458,000.00 | ★ $251,233,000.00 |
| Revenue This Year | $881.87 | $52.87 |
| Revenue Next Year | $230.67 | $6.07 |
| P/E Ratio | ★ N/A | $80.29 |
| Revenue Growth | ★ 324.10 | 64.83 |
| 52 Week Low | $3.07 | $93.58 |
| 52 Week High | $19.86 | $212.49 |
Technical Indicators
Market Signals| Indicator | EOSE | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 59.66 |
| Support Level | $11.17 | $186.48 |
| Resistance Level | $15.04 | $206.44 |
| Average True Range (ATR) | 0.76 | 5.91 |
| MACD | 0.26 | 0.64 |
| Stochastic Oscillator | 76.20 | 68.34 |
Price Performance
Historical ComparisonAbout EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.